Mini Review
Volume 14:3, 2023

Human Genetics and Embryology

ISSN: 2161-0436 Open Access

Human Embryonic Stem Cells in Regenerative Medicine

Zenimio Nemin*

Department of Genetics, University of Hebrew, Jerusalem, Israel

Abstract

In recent years, human Embryonic Stem Cells (hESCs) have emerged as a groundbreaking tool in the field of regenerative medicine. These pluripotent cells hold immense potential for treating a wide range of degenerative diseases, injuries, and congenital disorders. This article delves into the world of hESCs, exploring their unique properties, ethical considerations, current applications, and the future possibilities they offer in regenerative medicine.

Keywords: Human embryonic stem cells • Transplantation • Pluripotent stem cells

Introduction

Regenerative medicine aims to repair, replace, or rejuvenate damaged tissues or organs, offering new hope to individuals suffering from conditions that were once considered incurable. Human embryonic stem cells represent a pivotal component of this revolutionary approach. These cells are unique because they possess the remarkable ability to differentiate into any cell type in the human body, a property known as pluripotency. The production and differentiation of hESCs can be expensive and labor-intensive. Achieving cost-effective and scalable methods is a priority for widespread clinical applications. The ability to generate patient-specific hESC-derived cells holds great promise for personalized medicine. This involves creating cells tailored to an individual's genetic makeup, minimizing the risk of immune rejection [1].

Literature Review

ESCs can give rise to all three primary germ layers - ectoderm, endoderm, and mesoderm - from which all bodily tissues and organs originate. This remarkable potential makes them a versatile tool for tissue engineering and regenerative therapies. hESCs have the capacity for unlimited self-renewal. They can divide and replicate while maintaining their pluripotent state, ensuring a consistent supply of cells for research and therapy. Genetic plasticity cells can be genetically manipulated to study disease mechanisms, develop disease models, and potentially correct genetic defects. The use of hESCs has sparked ethical debates due to their origin from human embryos. The ethical concerns primarily revolve around the destruction of embryos and the potential for exploitation. To address these issues, various guidelines and regulations have been established in different countries to ensure responsible and ethical research involving hESCs. Ethical concerns surrounding hESC research continue to influence regulations and funding. Developing alternative cell sources like iPSCs may alleviate these concerns [2,3].

Discussion

Researchers are exploring hESCs as a source for generating various cell types needed for transplantation. Examples include cardiomyocytes for heart regeneration, dopaminergic neurons for Parkinson's disease, and pancreatic beta cells for diabetes. Drug screening and disease modelling are used to create disease models, allowing researchers to study diseases' molecular mechanisms and test potential drug candidates. Tissue engineering in hESCs are employed in tissue engineering to develop artificial organs, such as liver and kidneys, and to create functional tissues for transplantation. Toxicology testing are used in toxicology studies to assess the safety of pharmaceuticals and chemicals on human cells. The risk of immune rejection when transplanting hESC-derived cells remains a challenge. Researchers are investigating methods to reduce this risk, such as immune modulation and the creation of patient-specific cells through induced Pluripotent Stem Cells (iPSCs). ESCs have a propensity to form tumors, limiting their therapeutic potential. Strategies to ensure the safety of hESC-based therapies are under development [4-6].

Conclusion

Human embryonic stem cells have transformed the landscape of regenerative medicine by offering an unprecedented opportunity to repair and regenerate damaged tissues and organs. While ethical concerns and scientific challenges persist, the potential benefits for patients suffering from a myriad of conditions are undeniable. The ongoing research and development in this field continue to bring us closer to a future where hESCs play a pivotal role in curing previously incurable diseases and injuries, significantly improving the quality of life for countless individuals. As science and ethics evolve hand in hand, the responsible and ethical use of hESCs in regenerative medicine will likely lead to innovative breakthroughs in healthcare. The ability to generate patient-specific hESC-derived cells holds great promise for personalized medicine. This involves creating cells tailored to an individual's genetic makeup, minimizing the risk of immune rejection. Ethical concerns surrounding hESC research continue to influence regulations and funding. Developing alternative cell sources like iPSCs may alleviate these concerns.

Acknowledgement

None.

Conflict of Interest

There are no conflicts of interest by author.

References

1. Sagi, Ido, Gloryn Chia, Tamar Golan-Lev and Mordecai Peretz, et al. "Derivation and differentiation of haploid human embryonic stem cells." *Nature* 532 (2016): 107-111.

***Address for Correspondence:** Zenimio Nemin, Department of Genetics, University of Hebrew, Jerusalem, Israel, E-mail: nemin@zenimio.is*

Received: 17 July, 2023, Manuscript No. hgec-23-115033; **Editor Assigned:** 19 July, 2023, PreQC No. P-115033; **Reviewed:** 02 August, 2023, QC No. Q-115033; **Revised:** 07 August, 2023, Manuscript No. R-115033; **Published:** 14 August, 2023, DOI: 10.37421/2161-0436.2023.14.211

2. Bar, Shiran, Dan Vershkov, Gal Keshet and Elyad Lezmi, et al. "Identifying regulators of parental imprinting by CRISPR/Cas9 screening in haploid human embryonic stem cells." *Nat Commun* 12 (2021): 6718.

3. Yilmaz, Atilgan, Carmel Braverman-Gross, Anna Bialer-Tsypin and Mordecai Peretz, et al. "Mapping gene circuits essential for germ layer differentiation via loss-of-function screens in haploid human embryonic stem cells." *Cell Stem Cell* 27 (2020): 679-691.

4. Sarel-Gallily, Roni, Tamar Golan-Lev, Atilgan Yilmaz and Ido Sagi, et al. "Genome-wide analysis of haploinsufficiency in human embryonic stem cells." *Cell Reports* 38 (2022).

5. Kastan, Nathaniel, Ksenia Gnedeva, Theresa Alisch and Aleksandra A. Petelski, et al. "Small-molecule inhibition of Lats kinases may promote Yap-dependent proliferation in postmitotic mammalian tissues." *Nat Commun* 12 (2021): 3100.

6. Zimmermann, Astrid, Frank T. Zenke, Li-Ya Chiu and Heike Dahmen, et al. "A new class of selective ATM inhibitors as combination partners of DNA double-strand break inducing cancer therapies." *Mol Cancer Ther* 21 (2022): 859-870.

How to cite this article: Nemin, Zenimio. "Human Embryonic Stem Cells in Regenerative Medicine." *Human Genet Embryol* 14 (2023): 211.